Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Mar 25, 2026
Date Accepted: Aug 24, 2026

The final, peer-reviewed published version of this preprint can be found here:

Digital Prescription–Based Influenza Activity Forecasting in Jiangxi Province, China: Comparative Modeling Analysis Using Multisource Data

Yang R, Xu Z, Zhang C, Qiu L, Qian J, Liu J, Dong Y, Zeng Z, Shen R, Feng L

Digital Prescription–Based Influenza Activity Forecasting in Jiangxi Province, China: Comparative Modeling Analysis Using Multisource Data

J Med Internet Res 2026;28:e96131

DOI: 10.2196/96131

PMID: 42777171

Digital Prescription-Based Influenza Activity Forecasting in Jiangxi Province, China: A Comparative Modeling Analysis Using Multi-Source Data

  • Rongrong Yang; 
  • Zilu Xu; 
  • Chi Zhang; 
  • Liping Qiu; 
  • Jie Qian; 
  • Jie Liu; 
  • Yonghai Dong; 
  • Zhili Zeng; 
  • Rui Shen; 
  • Luzhao Feng

ABSTRACT

Background:

Influenza surveillance faces delays that hinder timely intervention. While search engine queries offer real-time monitoring, they are susceptible to noise and may not reflect true incidence. Digital antiviral prescription data capture genuine health-seeking behavior at the point of care, offering a potential alternative. However, the predictive validity of such data for influenza forecasting and their optimal integration within a multi-source modeling framework remains insufficiently evaluated.

Objective:

To evaluate the predictive utility of digital antiviral prescription data for influenza forecasting and propose a methodological framework linking source validation to multi-source predictive modeling.

Methods:

We conducted a longitudinal study using weekly province-level data from Jiangxi, China (2022–2024), integrating six data streams. We examined temporal relationships between digital prescription rates and influenza positivity rates using cross-correlation and Granger causality tests. We constructed 38 predictive features and, using a rolling forecasting method, evaluated LASSO alongside ARIMA, Random Forest, Prophet, and Explainable Boosting Machine for 1- to 8-week ahead predictions, with performance assessed using R² and RMSE.

Results:

Digital prescription rates exhibited a leading effect on influenza positivity rates, with the strongest correlation observed at a 1-week lead time, a finding further corroborated by Granger causality tests (P < .001 for all lags). LASSO demonstrated superior or comparable performance across most horizons, achieving the highest mean R2 (0.89) and lowest mean RMSE (4.52). LASSO consistently outperformed alternatives for 5- to 8-week horizons. Top predictors included 1- and 5-week lagged positivity rates and 1-week lagged prescription rates.

Conclusions:

Digital antiviral prescription data is a valid real-time leading indicator of influenza activity. LASSO provides an optimal balance of accuracy and interpretability within a multi-source data framework, offering a practical pathway for provincial influenza early warning.


 Citation

Please cite as:

Yang R, Xu Z, Zhang C, Qiu L, Qian J, Liu J, Dong Y, Zeng Z, Shen R, Feng L

Digital Prescription–Based Influenza Activity Forecasting in Jiangxi Province, China: Comparative Modeling Analysis Using Multisource Data

J Med Internet Res 2026;28:e96131

DOI: 10.2196/96131

PMID: 42777171

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.